Objective: The purpose of the study was to survey current G-CSF use in cancer patients, investigate whether the use of granulocyte colony-stimulating factor(G-CSF) is standardized. Methods: From July 2012 to October 2...Objective: The purpose of the study was to survey current G-CSF use in cancer patients, investigate whether the use of granulocyte colony-stimulating factor(G-CSF) is standardized. Methods: From July 2012 to October 2012, patients in a third-grade class-A hospital were investigated by self-designed questionnaires, according to ASCO's recommendations for white blood cell growth factors in 2006 and NCCN myeloid growth factors guideline in 2012. Results: Two hundred and twenty-two patients treated with 724 courses of chemotherapy were included. In prophylactic use, 259(35.8%) cases used G-CSF that the guideline doesn't recommend, which belonged to excessive use, the dose were 274 700 μg, accounting for 59.7% of the totle prophylactic use; 105(14.5%) didn't use while the guideline recommend, belonging to lack of use. 89.0% of the prophylactic use were 24–72 h after chemotherapy, only a few(5.4%) on the day of chemotherapy. In therapeutic use, only 3.1% were standardized, with the dose of 23 000 μg, accounting for 7.4% of the total. So 92.6% were excessive. 14.2% of the therapeutic use were 24–72 h after chemotherapy, 21.2% on the day of chemotherapy. Conclusion: More than 50% use of G-CSF weren't standardized, especially the excessive use.展开更多
文摘Objective: The purpose of the study was to survey current G-CSF use in cancer patients, investigate whether the use of granulocyte colony-stimulating factor(G-CSF) is standardized. Methods: From July 2012 to October 2012, patients in a third-grade class-A hospital were investigated by self-designed questionnaires, according to ASCO's recommendations for white blood cell growth factors in 2006 and NCCN myeloid growth factors guideline in 2012. Results: Two hundred and twenty-two patients treated with 724 courses of chemotherapy were included. In prophylactic use, 259(35.8%) cases used G-CSF that the guideline doesn't recommend, which belonged to excessive use, the dose were 274 700 μg, accounting for 59.7% of the totle prophylactic use; 105(14.5%) didn't use while the guideline recommend, belonging to lack of use. 89.0% of the prophylactic use were 24–72 h after chemotherapy, only a few(5.4%) on the day of chemotherapy. In therapeutic use, only 3.1% were standardized, with the dose of 23 000 μg, accounting for 7.4% of the total. So 92.6% were excessive. 14.2% of the therapeutic use were 24–72 h after chemotherapy, 21.2% on the day of chemotherapy. Conclusion: More than 50% use of G-CSF weren't standardized, especially the excessive use.
